Abdera Therapeutics
Rachael Brake is a seasoned scientific leader with extensive experience in biotechnology and pharmaceutical industries, currently serving as Chief Scientific Officer at Abdera Therapeutics since July 2025. Previously held Chief Scientific Officer positions at Zephyr AI and Corbus Pharmaceuticals, where a significant strategic transformation toward precision medicine was successfully executed. At Takeda Oncology, Rachael held multiple roles, including Global Program Lead and Head of US Medical Affairs Oncology, focusing on late-stage assets for non-small cell lung cancer. Rachael's career also includes leadership roles at Amgen and development positions at WAMIR Research Institute, with a strong emphasis on clinical development, strategic planning, and mentoring in cancer pharmacology. Rachael holds a PhD in Biochemistry/Molecular Biology from The University of Western Australia and a BSc with Honors in Molecular Biology/Biochemistry from The Australian National University.
This person is not in any teams
This person is not in any offices
Abdera Therapeutics
1 followers
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.